摘要
本文报告５４例海拔２３００～３７２０ｍ处慢性阻塞性肺疾病、肺心病患者使用新型β＿２受体激动剂特布唉的肺功能（ＶＣ．ＦＶＣ．ＦＥＶ＿（１．０）ＰＥＦＦＥＦ＿（５０））、动脉血气（ＰａＯ＿２ＰａＣＯ＿２ＳａｔＯ＿２）及临床疗效对比研究结果表明，特布嗪对慢阻肺、肺心病患者有较强的支气管扩张作用，降低气道高反应性，改善通气量，提高血氧分压，作用时间长，副作用较少，是临床治疗支气管痉挛迅速而有效的较好药物。
he paper reporied comparison of
clinical effects and pulrnonary function(VC, FVC, FEV_(1.0),PEF,
FEF_(50)) and aterial blood gas analysis(PaO_2,PaCO_2.SatO_2)of 54
Chronic Obstructive PulmonaryDisease (COPD ) and Cor pulmonale
patients treated by Tebuqin(Tubobulerol HydrorhOriAe),a kindof new β
_2-acceptor excitant at 2 300～3700 meters above sew level.The
results showed that Tebuqinhad strong effect of bronchiectasis and
decreased high reaction of the airway and improved vantilationreverse
and enhanced blfor PO_2. It had features of long time action and a
few side effects.It is a betterdrug to treat bronchospasm quickly and
effectively.
出处
《高原医学杂志》
CAS
1995年第3期24-26,共3页
Journal of High Altitude Medicine
